Prevalence and incidence of Parkinson's disease in The Faroe Islands

Acta Neurologica Scandinavica

Volumn 118, Issue 2, 2008, Pages 126-131

  Wermuth, L ^a   Bech, S ^b   Petersen, M Skaalum ^c   Joensen, P ^d   Weihe, P ^b,c   Grandjean, P ^c,e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d Neurologist in Private Practice and Consultant at the National Hospital   (Faroe Islands)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Concidence; Epidemiology studies; Parkinson's disease; Prevalence; The Faroe Islands

Indexed keywords

LEVODOPA;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DENMARK; DRUG DOSE COMPARISON; EPIDEMIOLOGICAL DATA; FAROE ISLANDS; FEMALE; GENDER; GROUPS BY AGE; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; ENVIRONMENT; FAMILY HEALTH; GENETICS; GEOGRAPHY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; ENVIRONMENT; FAMILY HEALTH; FEMALE; GEOGRAPHY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE;

EID: 55949115879     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00991.x     Document Type: Article

References (33)

1. DE PEDRO-CUESTA J. Parkinson's disease occurrence in Europe. Acta Neurol Scand 1991;84:357-65.
2. ANDERSON DW, ROCCA WA, DE RIJK MC et al. Case ascertainment uncertainties in prevalence surveys of Parkinson's Disease. Mov Disord 1998;13:626-32.
3. WERMUTH L, JOENSEN P, BÜNGER N, JEUNE B. High prevalence of Parkinson's disease in the Faroe Islands. Neurology 1997;49:426-32.
4. WERMUTH L, PAKKENBERG H, JEUNE B. High age-adjusted prevalence of Parkinson's disease among Inuit in Greenland. Neurology 2002;58:1422-5.
5. WERMUTH L, VON WEITZEL-MUDERSBACH P, JEUNE B. A two-fold difference in the age-adjusted prevalence of Parkinson's disease between the island of Als and the Faroe island. Eur J Neurol 2000;7:655-60.
6. TANDBERG E, LARSEN JP, NESSLER EG, RIISE T, AARLI JA. The epidemiology of Parkinson's disease in the County of Rogaland, Norway. Mov Disord 1995;10:541-9.
7. WERMUTH L, STENAGER EN, STENAGER E, BOLDSEN J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92:55-8.
8. BENNET DA, BECKETT LA, MURRAY AM et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-6.
9. LOUIS ED, MARDER K, COTE L, TANG M, MAYEUX R. Mortality from Parkinson's disease. Arch Neurol 1997;54:260-4.
10. DE PEDRO-CUESTA J, STAWIARZ L. Parkinson's disease incidence: magnitude, comparability, time trends. Acta Neurol Scand 1991;84:382-8.
11. CALNE DB, SNOW BJ, LEE C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992; 32(Suppl.): S125-7.
12. QUINN N. Parkinsonism: recognition and differential diagnoses. BMJ 1995;310:447-52.
13. LARSEN JP, DUPONT E, TANDBERG E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-51.
14. HUGHES AJ, DANIEL SE, BEN-SHLOMO Y, LEES AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70.
15. GILMAN S, LOW P, QUINN NP et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 1998;8:359-62.
16. LITVAN I, AGID Y, CALNE D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olzewski syndrome). Report of the NINDS-SPSP international Workshop. Neurology 1996;47:1-9.
17. RILEY DE, LANG AE. CBD. Clinical diagnostic criteria. Adv Neurol 2000;82:29-34.
18. ARBOK FYRI FÆEROYAR (YEARBOOK OF THE FAROE ISLANDS). SkulÆbokagrunnur. FÆroyear: Hagstovan (Statistical Bureau), 2005.
19. HOFMAN A, COLETTE HJA, BARTELDS AIM. Incidence and risk factors of Parkinson's disease in the Netherlands. Neuroepidemiology 1989;8:296-9.
20. VAN DEN EEDEN SK, TANNER CM, BERNSTEIN AL et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-22.
21. KUOPIO AM, MARTTILA RJ, HELENIUS H, RINNE UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999;52:302-8.
22. GUDMUNDSSON KRA. A clinical survey of parkinsonism in Iceland. Acta Neurol Scand 1967;43(Suppl. 33):9-61.
23. SCHRAG A, SCHOTT JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63.
24. HICKS AA, PÉTURSSON H, JÓNSSON T et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52:549-55.
25. MILMAN N, A STEIG T, KOEFOED P, PEDERSEN P, FENGER K, NIELSEN FC. Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Ann Hematol 2004;83:654-7.
26. HALLING J, PETERSEN MS, DAMKIER P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faro-ese population. Eur J Clin Pharmacol 2005;61:491-7.
27. COLLINS MA, NEAFSEY EJ. Potential neurotoxic "agents provocateurs" in Parkinson's disease. Neurotoxicol Tera-tol 2002;24:571-7.
28. ANDERSEN A, JUHLSHAMN K, RINGDAL O, MØRKØRE J. Trace elements intake in the Faroe Islands II. Intake of mercury and other elements by consumption of pilot whales (Globicephalus meleanus). Sci Total Environ 1987;65:63-8.
29. GRANDJEAN P, WEIHE P, JØRGENSEN PJ, CLARKSON T, CERNICHIARI E, VIDERØ T. Impact of maternal seafood diet on fetal exposure to mercury, selenium, and lead. Arch Environ Health 1992;47:185-95.
30. STEENLAND K, HEIN MJ, CASSINELLI RT et al. Polychlori-nated biphenyls and neurodegenerative disease mortality in an occupational cohort. Epidemiology 2006;17:8-13.
31. CAUDLE WM, RICHARDSON JR, DELEA KC et al. Poly-chlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicol Sci 2006; 92:490-9.
32. NGIM CH, DEVATHASAN G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-41.
33. BEMIS JC, SEEGAL RF. Polychlorinated biphenyls and methylmercury act synergistically to reduce rat brain dopamine content in vitro. Environ Health Perspect 1999;107:879-85.